Meet Marci, Invasive Lobular Breast Cancer Survivor and Signatera™ Patient

Marci was only 33 years old when her life changed by a diagnosis that had spent months hiding in plain sight. Marci was eventually diagnosed with invasive lobular carcinoma (ILC), a subtype of breast cancer notorious for its ability to evade conventional imaging. As a mother and a rural nurse, she suddenly found herself balancing the physical toll of aggressive therapy with the logistical challenges of accessing specialized care from a remote community.

“I was told when I was cancer free, which I was basing off of my first Signatera negative. It's better than winning the lottery,” she said.

For Marci, the traditional "wait and see" approach of standard imaging wasn't enough. She needed a more precise way to monitor her health. On her journey toward survivorship, she was introduced to Signatera by her oncologist, a tumor-informed ctDNA test designed to detect molecular residual disease (MRD).

“I feel like Signatera helped me take back some of my power,” Marci shares.

Quarterly Signatera tests, each returning a “not detected” result to date, have become her definitive measure of remission. While standard scans often left room for doubt, the blood test offered a level of tangible peace of mind that allowed her to focus on her family and her career.

Today, Marci continues to move forward every three months with confidence. By using Signatera to monitor for recurrence earlier than standard-of-care tools, she and her care team can make more informed decisions, ensuring that she stays one step ahead.